Abeona Signs Exclusive License Agreement with Regenxbio to Develop and Commercialize NAV AAV9 vector

Shots:

• Regenxbio to get $100M as total deal value plus $20M upfront ($10M paid on signing, $10M with 12 mos.) in addition to $60M milestone payment on sales
• Abeona to hold exclusive WW rights of Regenxbio’s NAV AAV9 vector, to develop gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 and CLN3
• Regenxbio’s NAV AAV9 vector is based on its NAV Technology Platform indicated for the treatment of systemic and CNS manifestations

Click here to read full press release/ article | Ref: Regenxbio | Image: Orphan Disease Center